A dangerous fungal germ has learned to completely outwit humanity – and it’s not the first time.
In a recent report, scientists in Kenya detailed a worrying case of Candidozyma auris found in a 28-year-old patient. The person’s infection was resistant to all major types of antifungal drugs, they found. According to the researchers, this particular strain may be unrelated to previous cases of pan resistance, suggesting that this fungus can repeatedly adapt to all of our available weapons against it.
The strain’s “resistance to four major antifungal classes highlights the growing threat of incurable fungal infections, particularly in settings where access to new antifungal agents is limited,” the authors wrote in their paper published late last month in the journal Scientific Reports.
An unfailing threat
C. auris (formerly known as Candida auris) has become one of the world’s most concerning superbug threats. Although many people carry the fungus on their skin harmlessly, it can cause serious, life-threatening infections in people with weakened immune systems or generally poor health. What makes C. auris What’s particularly frightening is that it is particularly adept at developing resistance to the drugs most commonly used to treat fungal infections.
The latter case was documented in a woman who attended a hospital for elective inpatient surgery. Subsequently, she developed a nosocomial infection at the surgical site. Although she was given antibiotics for a potential bacterial infection, she continued to suffer and a pus swab from the wound revealed the presence of C. auris. Researchers eventually confirmed that his strain was resistant to all four major classes of antifungals. According to the report, the hospital was made aware of the resistance of the strain to “facilitate the implementation of C. auris-specific infection prevention and control measures. However, the report does not detail what ultimately happened to the patient herself.
There have been several outbreaks and cases of highly resistant viruses C. auris reported over the years, and at least one confirmed case of infection resistant to all four major types of antifungals was reported in 2022. Although this is only the second such case documented worldwide, researchers say, there is an additional problem that makes this finding all the more worrying.
They sequenced the genome of the patient’s strain and found that it carried different resistance mutations than those found in the 2022 case. Although the researchers cannot completely rule out the possibility that their case came from the earlier strain, it is more likely that this lineage of C. auris The pan-resistance evolved independently, they argue.
A worrying future for superbugs
C. auris is still a relatively rare fungal infection, but its global burden has clearly increased over time. At least 6,304 cases have been reported in the United States in 2024, the highest number ever recorded, and it has been documented in at least 50 countries.
For the moment, completely incurable infections of C. auris are probably particularly rare. C. auris outbreaks can also be stopped with appropriate containment measures aside from antifungals. And scientists are working to develop other types of interventions, such as vaccines against the fungus. But if pan-resistance occurs regularly, there is always the risk that one of these strains will eventually spread widely and wreak havoc. C. auris even more of a nightmare to deal with.
Gn Health
